Physician profile
Jerome P Mathias
NPI 1780780551
$10,749.17
in general payments reported to CMS, 2019-2025
30 companies · $803 in 2025
The $803 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,926 · 2020: $621 · 2021: $2,952 · 2022: $1,635 · 2023: $1,592 · 2024: $1,221 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,615.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,615.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,343.79 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,305.97 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,063.19 | 2019-2025 | Farxiga, Andexxa |
| Merck Sharp & Dohme LLC | $989.62 | 2019-2025 | Verquvo, Capvaxive |
| Medtronic, INC. | $964.40 | 2021 | |
| Amgen INC. | $799.15 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $757.55 | 2019-2025 | |
| Novo Nordisk INC | $701.43 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $572.09 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $445.41 | 2020-2025 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $310.54 | 2019-2023 | |
| Lilly USA, LLC | $237.49 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Vifor Pharma, INC. | $189.25 | 2019-2022 | |
| Daiichi Sankyo INC. | $166.59 | 2024-2025 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.36 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $122.86 | 2019-2025 | |
| Medtronic Vascular, INC. | $118.88 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $94.76 | 2023-2024 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $87.01 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $73.97 | 2021-2025 | |
| Abbott Laboratories | $67.54 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $41.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $31.18 | 2019-2021 | |
| Edwards Lifesciences Corporation | $29.55 | 2019 | |
| Kestra Medical Technology Services, INC. | $25.67 | 2022 | |
| Lundbeck LLC | $20.98 | 2019 | |
| Atricure, INC. | $18.23 | 2024 | |
| Gilead Sciences, INC. | $12.66 | 2019 | |
| Irhythm Technologies, INC. | $12.62 | 2022 | |
| Si-Bone, INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerome Mathias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.